Krishna R. Polu

1.5k total citations · 1 hit paper
17 papers, 907 citations indexed

About

Krishna R. Polu is a scholar working on Hematology, Nephrology and Molecular Biology. According to data from OpenAlex, Krishna R. Polu has authored 17 papers receiving a total of 907 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Hematology, 5 papers in Nephrology and 3 papers in Molecular Biology. Recurrent topics in Krishna R. Polu's work include Erythropoietin and Anemia Treatment (7 papers), Iron Metabolism and Disorders (4 papers) and Renal Diseases and Glomerulopathies (3 papers). Krishna R. Polu is often cited by papers focused on Erythropoietin and Anemia Treatment (7 papers), Iron Metabolism and Disorders (4 papers) and Renal Diseases and Glomerulopathies (3 papers). Krishna R. Polu collaborates with scholars based in United States, United Kingdom and Poland. Krishna R. Polu's co-authors include Martin R. Pollak, Changli Wei, Carmen Ávila-Casado, Iván Villegas, Clemens Möller, Raghu Kalluri, Peter Mündel, Paula L. Smith, Jochen Reiser and David E. Clapham and has published in prestigious journals such as New England Journal of Medicine, Nature Genetics and Cancer Research.

In The Last Decade

Krishna R. Polu

17 papers receiving 883 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

TRPC6 is a glomerular slit diaphragm-associated channel required for normal renal function

2005 647 citations Jochen Reiser, Krishna R. Polu et al. Nature Genetics profile →

Peers

Countries citing papers authored by Krishna R. Polu

Since Specialization

Citations

This map shows the geographic impact of Krishna R. Polu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Krishna R. Polu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Krishna R. Polu more than expected).

Fields of papers citing papers by Krishna R. Polu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Krishna R. Polu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Krishna R. Polu. The network helps show where Krishna R. Polu may publish in the future.

Co-authorship network of co-authors of Krishna R. Polu

This figure shows the co-authorship network connecting the top 25 collaborators of Krishna R. Polu. A scholar is included among the top collaborators of Krishna R. Polu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Krishna R. Polu. Krishna R. Polu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	Itolizumab, a Novel Anti-CD6 Therapy, in Systemic Lupus Erythematosus Patients: Interim Safety Results from the Phase 1b EQUALISE Dose-Escalation Study 2021 ·Journal of the American Society of Nephrology ·Chaim Putterman, Richard Furie, Jai Radhakrishnan, Vandana Mathur, Krishna R. Polu, Stephen Connelly, (unknown), Cherie Ng, Leslie W. Chinn, Maple M. Fung, Dolca Thomas, Kenneth Kalunian	1
2	38 History of pulmonary exacerbations (PEx) as a predictor of response to nebulized levofloxacin compared with nebulized tobramycin 2016 ·Journal of Cystic Fibrosis ·Patrick A. Flume, J.S. Elborn, Krishna R. Polu, Lily Llorens, (unknown), Nirav Bhatt, Donald R. VanDevanter	8
3	37 Microbiologic changes observed over 6 months in a randomized, open-label comparison of inhaled levofloxacin and inhaled tobramycin in persons with cystic fibrosis and chronic P. aeruginosa (Pa) airway infection 2016 ·Journal of Cystic Fibrosis ·Donald R. VanDevanter, (unknown), Patrick A. Flume, Krishna R. Polu, John J. LiPuma	7
4	FO015AKB-6548, A NOVEL HYPOXIA-INDUCIBLE FACTOR PROLYL-HYDROXYLASE INHIBITOR (HIF-PHI) FOR THE TREATMENT OF ANEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE NOT ON DIALYSIS (ND-CKD) 2015 ·Nephrology Dialysis Transplantation ·Pablo E. Pérgola, Bruce Spinowitz, Volker H. Haase, (unknown), (unknown), Krishna R. Polu, Bradley J. Maroni, Robert A. Shalwitz	1
5	Abstract 2665: Transforming Notch ligands into tumor-antigen targets: A Probody-Drug Conjugate (PDC) targeting Jagged 1 and Jagged 2 2014 ·Cancer Research ·Jason Sagert, Jim West, Chihunt Wong, Luc Desnoyers, Olga Vasiljeva, Jennifer Richardson, Krishna R. Polu, Henry B. Lowman	6
6	Peginesatide in Patients with Anemia Undergoing Hemodialysis 2013 ·New England Journal of Medicine ·Steven Fishbane, Brigitte Schiller, Francesco Locatelli, Adrian Covic, Robert Provenzano, Andrzej Więcek, Nathan W. Levin, Mark Kaplan, Iain C. Macdougall, (unknown), Martha Mayo, Krishna R. Polu, Anne‐Marie Duliège, Anatole Besarab	69
7	Peginesatide for Anemia in Patients with Chronic Kidney Disease Not Receiving Dialysis 2013 ·New England Journal of Medicine ·Iain C. Macdougall, Robert Provenzano, Amit Sharma, Bruce Spinowitz, Rebecca J. Schmidt, Pablo E. Pérgola, Raja I. Zabaneh, Sandra Tong-Starksen, Martha Mayo, Hong Tang, Krishna R. Polu, Anne‐Marie Duliège, Steven Fishbane	78
8	Abstract C158: Tumor-specific inhibition of jagged-dependent notch signaling using a Probody™ therapeutic. 2013 ·Molecular Cancer Therapeutics ·Jason Sagert, James W. West, Olga Vasiljeva, Jennifer Richardson, Luc Desnoyers, Shouchun Liu, Annie Yang, Chihunt Wong, (unknown), Krishna R. Polu, Henry B. Lowman	3
9	PeginesatideforAnemiainPatientswith ChronicKidneyDiseaseNotReceivingDialysis 2013 ·Iain C. Macdougall, Robert Provenzano, (unknown), Bruce Spinowitz, Rebecca J. Schmidt, Pablo E. Pérgola, Raja I. Zabaneh, Sandra Tong-Starksen, Martha Mayo, Hong Tang, Krishna R. Polu, Anne‐Marie Duliège, Steven Fishbane	1
10	An open-label, sequential, dose-finding study of peginesatide for the maintenance treatment of anemia in chronic hemodialysis patients 2012 ·BMC Nephrology ·Anatole Besarab, Steven Zeig, Edouard Martin, Pablo E. Pérgola, Frederick C. Whittier, Raja I. Zabaneh, Brigitte Schiller, Martha Mayo, (unknown), Krishna R. Polu, Anne‐Marie Duliège	8
11	Dose-finding Study of Peginesatide for Anemia Correction in Chronic Kidney Disease Patients 2011 ·Clinical Journal of the American Society of Nephrology ·Iain C. Macdougall, Andrzej Więcek, Beatriz Tucker, Magdi Yaqoob, Ashraf Mikhail, Michał Nowicki, Iain MacPhee, M Myśliwiec, (unknown), Władysław Sułowicz, Martha Mayo, (unknown), Krishna R. Polu, Peter J. Schatz, Anne‐Marie Duliège	18
12	33 Safety and Efficacy of Peginesatide for Treatment of Anemia in Hemodialysis Patients Previously on Epoetin Alfa or Beta 2011 ·American Journal of Kidney Diseases ·Anatole Besarab, Francesco Locatelli, Adrian Covic, Edouard Martin, (unknown), Iain C. Macdougall, Hong Tang, Martha Mayo, Krishna R. Polu, Anne‐Marie Duliège	1
13	274 Safety and Efficacy of Peginesatide for Treatment of Anemia in Hemodialysis Patient Previously on Epoetin Alfa 2011 ·American Journal of Kidney Diseases ·Brigitte Schiller, Steven Zeig, (unknown), Nathan W. Levin, Mark Kaplan, Hong Tang, Martha Mayo, Krishna R. Polu, Anne‐Marie Duliège	1
14	NPHS2variation in focal and segmental glomerulosclerosis 2008 ·BMC Nephrology ·Stephen Tonna, (unknown), Krishna R. Polu, (unknown), Gerald B. Appel, Ronald J. Falk, A. Katz, Salah Al-Waheeb, Bernard S. Kaplan, George Jerums, Judy Savige, Jennifer N. Harmon, Kang Zhang, Gary C. Curhan, Martin R. Pollak	38
15	Needle in a Haystack 2006 ·New England Journal of Medicine ·Krishna R. Polu, Myles Wolf	8
16	TRPC6 is a glomerular slit diaphragm-associated channel required for normal renal function breakdown → 2005 ·Nature Genetics ·Jochen Reiser, Krishna R. Polu, Clemens Möller, (unknown), Mehmet M. Altintas, Changli Wei, Christian Faul, (unknown), Iván Villegas, Carmen Ávila-Casado, (unknown), Hikaru Sugimoto, Dennis Brown, Raghu Kalluri, Peter Mündel, Paula L. Smith, David E. Clapham, Martin R. Pollak	647
17	Stress Fracture of the Humerus in a Collegiate Baseball Pitcher 1999 ·The American Journal of Sports Medicine ·Krishna R. Polu, Robert C. Schenck, Michael A. Wirth, (unknown), (unknown), Charles A. Rockwood	12

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact